Manufacturing Facilities
Delivering high quality products across the globe
Monroe, US
Spread across 105,000 sq.ft., this facility will manufacture sterile and oral solids, injectable and nebulized products.
Estimated investment is approximately USD 100 Mn over 5 years.
Regulatory Approvals
- US-FDA
Markets
USA
Annual Capacity
Oral solids: 300 - 400 Mn tablets and capsules
Injectables: 20 - 25 Mn vials and pre-filled syringes
Inhalation: 25 - 30 mn ampules
Goa, India
The facility commenced operations in 2004.
Three manufacturing facilities for production of:
- Oral – solids
- Semi-solids
- Hormones (oral solids)
ISO 14001: 2015, ISO 45001: 2018
Regulatory Approvals
- US-FDA
- MCC South Africa
- WHO – GMP
- ANVISA Brazil
- MHRA UK
- RU – GMP Russia
- SUKL - CZ
Markets
North America, Western Europe
Annual Capacity
Oral solid dosages (OSD): 400 Mn tablets and 100 Mn capsules
Semi-solids: 2.75 Mn tubes
Hormone: 40 Mn tablets
Baddi, India
This state-of-the-art manufacturing facility commenced operations in 2005.
The facility caters to the production of oral solids and liquid orals, external preparations like lotions, creams and respiratory segment products.
ISO 14001: 2015 approved, ISO 45001: 2018
Regulatory Approvals
- WHO GMP
- US FDA
- ANVISA BRAZIL
- UK-MHRA (EU)
- SUKL- CZECH REPUBLIC
- UKRAINIAN-GMP
- MCC
- MOH RUSSIA
- ZAZIBONA
- NAMIBIA MEDICINES REGULATORY COUNCIL NAMIBIA
- ZIMBABWE
- TFDA TANZANIA
- ZANZIBAR
- GULF CO-OPERATION COUNCIL (GCC)
- RU-GMP
- MEXICO (COFEPRIS)
Markets
USA, Europe, India, Brazil, Ukraine, Russia, Argentina & Mexico, Other semi-regulated markets for specific dosage forms
Annual Capacity
Oral solids: 900 Mn tablets / capsules
Liquids: 40 Mn bottles
Semisolids: 20 Mn Tubes/Bottles
Respiratory segment: 15 Mn Units
Nalagarh, India
The facility commenced operations in 2009.
The plant has three main sections for manufacturing liquid, ointments/creams and lotions.
ISO 14001: 2004 approved, ISO 22716 : GMP for Cosmetics
Regulatory Approvals
- FDA Philippines
- TFDA - Tanzania
- NDA – Uganda
- FDA- Kenya
- WHO-GMP
- Local FDA
Markets
India, Asia, Africa
Annual Capacity
Oral liquids: 64 million bottles
Ointments and creams: 64 million units
Lotions: 32 million bottles
Sikkim, India
Established in 2012, the facility is focused on manufacturing oral solid dosages.
ISO 14001: 2015 Approved, ISO 45001: 2018 Approved
Regulatory Approvals
- Local FDA
Markets
India
Annual Capacity
Oral Solid dosages : 1650 million tablets
Nashik, India
Glenmark’s first manufacturing unit, it began operations in 1983.
The facility manufactures products catering to demand in oral solids, liquid orals, external creams and powder shampoo.
ISO 14001: 2015, OHSAS 45001: 2018
Regulatory Approvals
- WHO – GMP
- ANVISA (Brazil)
- NDA – Uganda
- MOH – Nigeria
- TFDA – Tanzania
- MOH – Ethiopia
- MOH – Congo
- UKRAINIAN -GMP
- MCC – South Africa
- MOH – Oman
- MOH – Ukraine
- INVIMA – Columbia
- SAUMP-Ukraine
- RU – GMP Russia
Markets
Asia, India, Africa, CIS / Russia, Latin America
Annual Capacity
Oral solids: 222 Mn tablets / capsules per year
Oral Liquids: 15.6 Mn bottles per year
External preparations: 48 Mn units per year
Powder Shampoo: 2.4 Mn units per year
Indore, India
The Indore facility initiated operations in May 2009.
ISO 14001: 2004 approved
Regulatory Approvals
- US-FDA
- UK MHRA
- WHO – GMP
Markets
North America, Europe
Annual Capacity
Oral solid dosages: 1490 Mn tablets
Immuno Suppressant Block:Capsules – 42 Mn
Ointment & Creams – 80 MT
Buenos Aires, Argentina
The Glenmark manufacturing site at Buenos Aires, Argentina is focused on manufacturing of Oncology Injectables.
The plant is spread across 30,000 sq. ft. and it serves as a global hub for manufacturing Lyophilized and Liquid Injectables used in oncology therapies.
ISO 14001: 2015 approved , ISO 45001: 2018 approved
Regulatory Approvals
- ANMAT Local MOH
- ANVISA Brazil
- INVIMA Colombia
- COFEPRIS Mexico
- SFDA Saudi Arabia
- MCC South Africa
- GCC UAE – KSA
- DRAP Pakistan
- Ukrainian GMP
- Sudan GMP
- Syrian Arab Republic GMP
- CHMP Kenya
Markets
Brazil, Mexico, Argentina, Vietnam, Indonesia, Caribbean countries, Other Latin American, Middle East and African countries
Annual Capacity
Injectables:
Liquid – 3 Mn Vials
Lyophilized – 1.3 Mn Vials
Vysoke Myto, Czech Republic
This manufacturing facility, formerly known as Medicamenta, was set-up in 1952 and was acquired by Glenmark in 2007. Presently the facility manufactures solid-orals.
OHSAS certification
Regulatory Approvals
- Manufacturing licence for medicinal products (Issued by SUKL)
- Distribution licence for medicinal products (Issued by SUKL)
- Certificate of GMP Compliance of Manufacturer (Issued by SUKL)
Markets
Czech Republic, Slovakia, Poland
Annual Capacity
Oral solid dosages: 200 Mn tablets
Aurangabad, India
Glenmark’s Aurangabad facility initiated operations in April 2012. Aurangabad site is focused in the manufacturing of Formulations (OSD, Inhaler & Foam). This plant is spread over 30 acres and it serves to both domestic and international markets.
ISO 14001: 2015 approved, ISO 45001: 2018 approved
Regulatory Approvals
- US-FDA
- SUKL
- WHO – GMP
- ANMAT
- ANVISA
Markets
ROW, Domestic, US, Brazil, EU
Annual Capacity
Tablet : 16 Mn
MDI : 3.5 Mn
DPI Device : 2 Mn
Topical Foam : 0.6 Mn
